Novel role for the CRTC2 in lipid homeostasis

Insulin resistance, a state of reduced responsiveness to insulin, is frequently associated with obesity, which subsequently leads to type 2 diabetes. Although major advances have been made in unraveling the underlying mechanisms that cause insulin resistance, many of the pathways and regulators that link insulin to its downstream metabolic effects are not completely understood.

Studies in rodent models showed a peculiar feature of hepatic insulin resistance, namely its selectivity. Insulin exerts two predominant actions in the liver: (i) it suppresses glucose production (gluconeogenesis); and (ii) it activates the synthesis of fatty acids and triglycerides (lipogenesis). However, in the insulin-resistance state, insulin fails to suppress gluconeogenesis, and lipogenesis is paradoxically overactivated. As suggested by Brown and Goldstein, the signaling pathways utilized by insulin to stimulate sterol regulatory element-binding protein (SREBP)-1c could remain intact in obesity and type 2 diabetes, even as the pathways that regulate glucose metabolism become resistant. These dual actions contribute to the lethal combination of hyperglycemia and hypertriglyceridemia that characterizes the diabetic state.

Increased lipogenesis observed in the insulin-resistant state is partially because of dysregulation of the master transcriptional regulator of lipogenesis, the SREBP-1c. The SREBP family consists of three isoforms: SREBP-1a, SREBP-1c and SREBP-2. SREBP-1c is an isoform that controls the biosynthesis of fatty acids and triglycerides by increasing transcription of genes encoding acetyl-CoA carboxylase, fatty acid synthase, elongation of very long chain fatty acids family member 6, stearoyl-CoA desaturase and others. Insulin activates SREBP-1c through at least two mechanisms: (i) it increases SREBP-1c transcription; and (ii) it increases the proteolytic cleavage of SREBP-1c from an inactive endoplasmic reticulum membrane-bound precursor to release their N-terminal domain capable of translocating to the nucleus to activate transcription (Figure 1).

In hepatocytes, insulin signaling through phosphatidylinositols 3-kinase and Akt results in the activation of SREBP-1c and accumulation of nuclear SREBP-1c protein. The mammalian target of rapamycin complex 1 (mTORC1) is the major phosphatidylinositol 3-kinase/Akt downstream effector, because insulin-stimulated SREBP activation and lipogenesis are both blocked by the mTORC1 inhibitor rapamycin. In addition, lipin-1, a phosphatidic acid

*Corresponding author. Takashi Matsuzaka
Tel.: +81-29-863-2081
Fax: +81-29-863-2081
E-mail address: t-matsuz@md.tsukuba.ac.jp
Received 3 February 2016; revised 8 February 2016; accepted 8 February 2016

© 2016 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd
J Diabetes Investig Vol. 7 No. 5 September 2016 677
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
phosphatase and transcriptional coactivator, is a direct substrate of mTORC1 and regulator of nuclear SREBP activity. Lipin-1 phosphorylation by mTORC1 blocks lipin’s nuclear localization and activates SREBP-1c activity. In the insulin-resistant state, insulin might continue to activate mTORC1 while losing its ability to inhibit forkhead box O1.

The cyclic adenosine monophosphate (cAMP) response element-binding protein (CREB)-regulated transcription coactivators (CRTC) physically interact with CREB through its N-terminal portion, and coactivate the transcriptional activity of CREB through its C-terminally located transactivation domain. cAMP-dependent activation of this transcriptional machinery promotes hepatic gluconeogenic programs by upregulation of key enzyme genes, such as phosphoenolpyruvate carboxykinase and glucose-6-phosphatase catalytic subunit Registry. Although the function of CRTC2 in the liver has been extensively studied in the context of gluconeogenesis, Han et al.5 recently showed that cytosolic CRTC2, as a critical mediator of mTOR, modulates coat protein complex II (COPII) activity, which subsequently leads to SREBP-1 processing and enhancement of de novo lipogenesis.

These authors measured hepatic lipid levels in Crtc2+/+ and Crtc2−/− mice. They found that Crtc2−/− mice showed increased hepatic triglyceride levels, but not cholesterol, when compared with Crtc2+/+ mice fed with both regular chow and a high-fat diet. Transcript analysis showed specific upregulation of SREBP1-target genes involved in triglyceride synthesis in the livers of Crtc2−/− mice. In Crtc2−/− mice fed with both chow and a high-fat diet, the active, nuclear SREBP-1 was significantly increased while the precursor, full-length SREBP-1 was slightly decreased, although total Srebp-1c mRNA levels remained unchanged. These results suggest that CRTC2 mediates SREBP-1 activity at the post-transcriptional level. In addition, the abnormal nuclear SREBP-1 accumulation and the enhanced lipogenic gene expression in Crtc2−/− mice were normalized to the level found in fed Crtc2+/+ mice by adenovirus-mediated CRTC2 overexpression or knockdown of Srebp-1. Taken together, these results show that CRTC2 modulates triglyceride synthesis through regulation of SREBP-1 maturation.

In the liver, cAMP signaling activates CRTC2 activity through Ser171 dephosphorylation resulting in its nuclear localization and increased association with CREB on the promoters of gluconeogenic genes. Han et al.5 examined the effects of the cellular localization of CRTC2 on SREBP1 maturation using two CRTC2 mutants: (i) ΔTAD (amino acids 1–630), which lacks the transactivation domain, but still shuttles between the cytoplasm and nucleus; and (ii) ΔTAD/AA, which is confined to the nucleus because of serine-to-alanine mutations at positions 171 and 275. Similar to wild-type CRTC2, the ΔTAD mutant also blocks SREBP-1 maturation in Crtc2−/− mice, whereas ΔTAD/AA mutant was not able to suppress the processing of SREBP-1, suggesting that SREBP-1 processing depends on cytosolic but not nuclear CRTC2.

Using mass spectrometry and co-immunoprecipitation analysis, they found that CRTC2 binds to proteins involved in SREBP-1 transport regulation. Insulin regulates SREBP activity through stimulation of endoplasmic reticulum-to-Golgi SREBP-1c transport by promoting its phosphorylation and association with COPII vesicles. Indeed, CRTC2 binds to Sec31A, a subunit of the COPII complex, and negatively regulates SREBP-1 processing by competing with Sec23A for stimulation of lipogenesis, and provides new insight into how SREBP-1 activity is enhanced in obesity and type 2 diabetes. This study thus identifies mTOR-CRTC-SREBP-1 signaling as a potential therapeutic target for ameliorating hyperglycemia, hypertriglyceridemia and hepatic steatosis in type 2 diabetes. Further unveiling of the molecular mechanisms(s) that regulate this signaling axis in obesity and diabetes will hopefully result in effective ways to overcome insulin resistance and provide a basis for beneficial treatment of type 2 diabetes.

DISCLOSURE
The authors declare no conflict of interest.

Takashi Matsuzaka*, Hitoshi Shimano
Department of Internal Medicine (Endocrinology and Metabolism), Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan

REFERENCES
1. Li S, Brown MS, Goldstein JL. Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis. Proc Natl Acad Sci USA 2010; 107: 3441–3446.
2. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. *J Clin Invest* 2002; 109: 1125–1131.

3. Altarejos JY, Montminy M. CREB and the CRTC co-activators: sensors for hormonal and metabolic signals. *Nat Rev Mol Cell Biol* 2011; 12: 141–151.

4. Wang Y, Inoue H, Ravnskaer K, et al. Targeted disruption of the CREB coactivator Crtc2 increases insulin sensitivity. *Proc Natl Acad Sci USA* 2010; 107: 3087–3092.

5. Han J, Li E, Chen L, et al. The CREB coactivator CRTC2 controls hepatic lipid metabolism by regulating SREBP1. *Nature* 2015; 524: 243–246.

Doi: 10.1111/jdi.12497